Zanubrutinib Combined With BR in the First-line Treatment of Waldenstrm's Macroglobulinemia
Status:
NOT_YET_RECRUITING
Trial end date:
2029-04-30
Target enrollment:
Participant gender:
Summary
Current retrospective studies have demonstrated that achieving deep remission following treatment for Waldenstrm's macroglobulinemia (WM) correlates with prolonged survival. While the bendamustine-rituximab (BR) regimen or single-agent zanubrutinib are currently recommended as first-line therapies, neither achieves optimal deep remission. Additionally, prolonged zanubrutinib monotherapy may lead to cumulative adverse effects. Therefore, this study aims to evaluate the efficacy and safety of the bendamustine-rituximab-zanubrutinib combination regimen as a first-line treatment option for MYD88-mutated WM patients.